{"id":30730,"date":"2025-03-27T15:24:27","date_gmt":"2025-03-27T07:24:27","guid":{"rendered":"https:\/\/flcube.com\/?p=30730"},"modified":"2025-03-27T15:24:29","modified_gmt":"2025-03-27T07:24:29","slug":"bio-thera-solutions-inks-licensing-deal-with-dr-reddys-for-biosimilar-commercialization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30730","title":{"rendered":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization"},"content":{"rendered":"\n

Guangzhou-based Bio-Thera Solutions (SHA: 688177<\/a>) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera’s BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.<\/p>\n\n\n\n

Commercialization Rights and Responsibilities<\/strong>
Dr. Reddy\u2019s has secured exclusive distribution and sales rights for BAT2206 and BAT2506 in Southeast Asian markets, including Cambodia, Indonesia, Malaysia, the Philippines, and Thailand. The company is responsible for regulatory filing and commercialization in these countries. Additionally, Dr. Reddy\u2019s will hold exclusive commercialization rights for BAT2206 in the Colombian market.<\/p>\n\n\n\n

Regulatory Status<\/strong>
BAT2206 is currently awaiting regulatory decisions in China, the US, and the European Union (EU), while BAT2506 is under review in China and the EU.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s…<\/p>\n","protected":false},"author":1,"featured_media":30731,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[289,43,762,149,1055],"class_list":["post-30730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-bio-thera-solutions","tag-biosimilars","tag-dr-reddys-laboratories","tag-johnson-johnson","tag-sha-688177"],"yoast_head":"\nBio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30730\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization\" \/>\n<meta property=\"og:description\" content=\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30730\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T07:24:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T07:24:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization\",\"datePublished\":\"2025-03-27T07:24:27+00:00\",\"dateModified\":\"2025-03-27T07:24:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2710-png.webp\",\"keywords\":[\"Bio-Thera Solutions\",\"Biosimilars\",\"Dr. Reddy's Laboratories\",\"Johnson & Johnson\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30730#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30730\",\"name\":\"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2710-png.webp\",\"datePublished\":\"2025-03-27T07:24:27+00:00\",\"dateModified\":\"2025-03-27T07:24:29+00:00\",\"description\":\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30730\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2710-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2710-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30730#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization - Insight, China's Pharmaceutical Industry","description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30730","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization","og_description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.","og_url":"https:\/\/flcube.com\/?p=30730","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-27T07:24:27+00:00","article_modified_time":"2025-03-27T07:24:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30730#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30730"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization","datePublished":"2025-03-27T07:24:27+00:00","dateModified":"2025-03-27T07:24:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30730"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30730#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","keywords":["Bio-Thera Solutions","Biosimilars","Dr. Reddy's Laboratories","Johnson & Johnson","SHA: 688177"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30730#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30730","url":"https:\/\/flcube.com\/?p=30730","name":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30730#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30730#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","datePublished":"2025-03-27T07:24:27+00:00","dateModified":"2025-03-27T07:24:29+00:00","description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera's BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson\u2019s Simponi (golimumab). Dr. Reddy\u2019s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30730#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30730"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30730#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","width":1080,"height":608,"caption":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30730#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2710-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30730"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30730\/revisions"}],"predecessor-version":[{"id":30732,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30730\/revisions\/30732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30731"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}